RT Journal Article
SR Electronic
T1 Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 922
OP 927
DO 10.2967/jnumed.111.101006
VO 53
IS 6
A1 Paola A. Erba
A1 Martina Sollini
A1 Enrico Orciuolo
A1 Claudio Traino
A1 Mario Petrini
A1 Giovanni Paganelli
A1 Emilio Bombardieri
A1 Chiara Grana
A1 Leonardo Giovannoni
A1 Dario Neri
A1 Hans D. Menssen
A1 Giuliano Mariani
YR 2012
UL http://jnm.snmjournals.org/content/53/6/922.abstract
AB We present here a systematic analysis of lymphoma and MM patients recruited into 2 clinical trials or treated with radretumab according to compassionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab. Methods: Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed lymphoma or multiple myeloma patients. Results: In 14 of 18 patients, selective tumor uptake was found; 11 of 15 lymphoma patients, including 9 of 11 with Hodgkin lymphoma (HL), were eligible for R-RIT (a priori criteria–based target-to-bone marrow ratio > 10:1 for EudraCT no. 2005-000545 or > 4:1 for EudraCT no. 2007-007241-12 at dosimetric imaging). Two HL and 1 diffuse large B cell lymphoma patient achieved complete response; 1 HL patient had partial response. Both multiple myeloma patients receiving R-RIT experienced stabilization of disease. Therefore, the overall objective response rate was 40%. Uncomplicated grade 3–4 thrombocytopenia or leukocytopenia was observed in 5 R-RIT patients, lasting 4–129 d. Conclusion: R-RIT showed a favorable benefit and risk profile in advanced relapsed lymphoma patients and induced complete response in 2 heavily pretreated, relapsed HL patients and in 1 diffuse large B cell lymphoma patient. These results warrant further exploration of R-RIT in larger phase II clinical trials.